Nearly 43% of patients with non-small cell lung cancer (NSCLC) whose lung cancers harbored a specific KRAS mutation responded to the experimental drug adagrasib, and the targeted agent also showed activity against lesions in the brain that metastasized from the lung tumors, according to results of a new study. https://www.sciencedaily.com/releases/2022/06/220603155423.htm
Breaking News
THE DATA ORGANISATION
Targeted drug achieves 43% response rate in KRAS-mutated lung cancer
Artificial Intelligence
June 3, 2022